| Abciximab | A monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention. |
| Eptifibatide | A peptide-based antagonist for glycoprotein IIb/IIIa used in the medical management of myocardial infarction and as an adjunct to percutaneous coronary intervention. |
| Ticlopidine | A platelet aggregation inhibitor used in the prevention of conditions associated with thrombi, such as stroke and transient ischemic attacks (TIA). |
| Treprostinil | A prostacyclin vasodilator for the treatment of pulmonary arterial hypertension to relieve exercise associated symptoms and to prevent clinical deterioration after stopping epoprostenol. |
| Clopidogrel | An antiplatelet agent used to prevent blood clots in peripheral vascular disease, coronary artery disease, and cerebrovascular disease. |
| Tirofiban | A platelet aggregation inhibitor used to prevent thrombotic events in non-ST elevated acute coronary syndrome. |
| Dipyridamole | A phosphodiesterase inhibitor used to prevent postoperative thromboembolic events. |
| Iloprost | A synthetic prostacyclin analog indicated to treat pulmonary arterial hypertension (PAH). |
| Cilostazol | An antiplatelet agent and vasodilator used for the symptomatic relief of intermittent claudication. |
| Epoprostenol | A vasodilator and platelet aggregation inhibitor used for the management of primary pulmonary hypertension and pulmonary hypertension in patients with heart failure. |
| Beraprost | For the treatment of pulmonary hypertension. |
| Prasugrel | A P2Y12 platelet inhibitor used to reduce risk of thrombotic cardiovascular events in unstable angina or non-ST-elevation myocardial infarction (NSTEMI), and in patients with STEMI when managed with either primary or delayed PCI. |
| Cangrelor | A P2Y12 platelet receptor antagonist used during percutaneous coronary intervention to reduce the risk for periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST). |
| Triflusal | Triflusal is indicated as prophylaxis of thromboembolic disorders. It has been registered in Spain and in other countries of Europe, South America and South Korea for the prevention of Stroke... |
| Ticagrelor | A P2Y12 platelet inhibitor used in patients with a history of myocardial infarction or with acute coronary syndrome (ACS) to prevent future myocardial infarction, stroke and cardiovascular death. |
| Ditazole | Ditazole is a non-steroidal anti-inflammatory drug (NSAID). Ditazole's analgesic and antipyretic effects are similar to phenylbutazone. Additionally, ditazole is a platelet aggregation inhibitor marketed in Spain and Portugal with trade... |
| Vorapaxar | A platelet aggregation inhibitor used to reduce thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). |
| Selexipag | A non prostanoid IP prostacyclin receptor agonist used to treat pulmonary arterial hypertension. |
| Indobufen | Indobufen has been used in trials studying the supportive care and prevention of Atrial Fibrillation. |
| Picotamide | Not Annotated |
| Cloricromen | Not Annotated |
| Aloxiprin | Not Annotated |
| Acetylsalicylic acid | A salicylate used to treat pain, fever, inflammation, migraines, and reducing the risk of major adverse cardiovascular events. |
| Carbaspirin calcium | Not Annotated |